Evidence map›Paper›PMID 35384688›Full record

ReviewInfection and immunity2022

The Age of Next-Generation Therapeutic-Microbe Discovery: Exploiting Microbe-Microbe and Host-Microbe Interactions for Disease Prevention.

Nathan Cruz, George A Abernathy, Armand E K Dichosa, Anand Kumar

Abstract readReview
In one paragraph

Review in Infection and immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Current and emerging approaches to manage chronic inflammatory gut disorders.Frontiers in cellular and infection microbiology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. The porcine skin microbiome exhibits broad fungal antagonism.Fungal genetics and biology : FG & B · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nathan Cruz *B-10: Biosecurity and Public Health Group, Bioscience Division, Los Alamos National Laboratorygrid.148313.c, Los Alamos, New Mexico, USA.
George A Abernathy *B-10: Biosecurity and Public Health Group, Bioscience Division, Los Alamos National Laboratorygrid.148313.c, Los Alamos, New Mexico, USA.ORCID 0000-0002-1336-3631
Armand E K DichosaB-10: Biosecurity and Public Health Group, Bioscience Division, Los Alamos National Laboratorygrid.148313.c, Los Alamos, New Mexico, USA.ORCID 0000-0003-0640-6629
Anand KumarB-10: Biosecurity and Public Health Group, Bioscience Division, Los Alamos National Laboratorygrid.148313.c, Los Alamos, New Mexico, USA.ORCID 0000-0001-9290-0927

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Humans are considered "superorganisms," harboring a diverse microbial collective that outnumbers human cells 10 to 1. Complex and gravely understudied host- and microbe-microbe interactions-the product of millions of years of host-microbe coevolution-govern the superorganism in almost every aspect of life functions and overall well-being. Abruptly disrupting these interactions via extrinsic factors has undesirable consequences for the host. On the other hand, supplementing commensal or beneficial microbes may mitigate perturbed interactions or enhance the interactive relationships that ultimately benefit all parties. Hence, immense efforts have focused on dissecting the innumerable host- and microbe-microbe relationships to characterize if a "positive" or "negative" interaction is at play and to exploit such behavior for broader implications. For example, microbiome research has worked to identify and isolate naturally antipathogenic microbes that may offer therapeutic potential either in a direct, one-on-one application or by leveraging its unique metabolic properties. However, the discovery and isolation of such desired therapeutic microbes from complex microbiota have proven challenging. Currently, there is no conventional technique to universally and functionally screen for these microbes. With this said, we first describe in this review the historical (probiotics) and current (fecal microbiota or defined consortia) perspectives on therapeutic microbes, present the discoveries of therapeutic microbes through exploiting microbe-microbe and host-microbe interactions, and detail our team's efforts in discovering therapeutic microbes via our novel microbiome screening platform. We conclude this minireview by briefly discussing challenges and possible solutions with therapeutic microbes' applications and paths ahead for discovery.

Indexed as

MicrobiotaProbioticsFecesHost Microbial InteractionsHumansMicrobial Interactionsdefined microbial consortiafecal microbiota transplanthost-microbe interactionsmicrobe-microbe interactionsnext-generation sequencingprobioticstherapeutic microbesunculturables

Identifiers

PMID35384688
PMCPMC9119102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.